e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Exhaled biomarkers: smells like disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Determination of volatile organic compounds in exhaled breath of patients with chronic obstructive pulmonary disease by gas chromatography mass spectrometry
R. Cortés, A. Guaman, I. Agudo, D. Calvo, A. Pardo, S. Marco, J. A. Barberà, F. P. Gómez, M. Cascante (Barcelona, Spain)
Source:
Annual Congress 2010 - Exhaled biomarkers: smells like disease
Session:
Exhaled biomarkers: smells like disease
Session type:
Thematic Poster Session
Number:
1266
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Cortés, A. Guaman, I. Agudo, D. Calvo, A. Pardo, S. Marco, J. A. Barberà, F. P. Gómez, M. Cascante (Barcelona, Spain). Determination of volatile organic compounds in exhaled breath of patients with chronic obstructive pulmonary disease by gas chromatography mass spectrometry. Eur Respir J 2010; 36: Suppl. 54, 1266
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Discrimination of protein and peptide composition of exhaled breath condensate in patients with pulmonary disease by mass spectrometry
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Differential ion mobility spectrometry for detection of metabolites in exhaled breath in airway diseases
Source: Annual Congress 2009 - Airway inflammation and asthma control
Year: 2009
Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis
Source: Eur Respir J 2006; 27: 929-936
Year: 2006
Expiratory gas analysis using mass spectrometry in chronic obstructive pulmonary disease
Source: International Congress 2019 – Research and innovation in airway diseases
Year: 2019
Detection of infectious agents in the airways by ion mobility spectrometry in exhaled breath
Source: Annual Congress 2010 - Mechanisms of respiratory infections
Year: 2010
Phenotyping of patients with COPD from exhaled air by ion mobility spectrometry
Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation
Year: 2012
SELDI-TOF MS for proteomic analysis of exhaled breath condensate from patients with pulmonary emphysema
Source: Annual Congress 2009 - COPD: basic science and clinical studies
Year: 2009
Exhaled breath analysis by ion mobility spectrometry in children with asthma and cystic fibrosis
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018
Volatile organic compounds (VOC) in exhaled breath in patients with lung cancer, using the analytical technique thermal desorber- gase chromatography-spectrometer mases
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
High performance liquid chromatography analysis of nitrosothiols and nitrite in exhaled breath condensate in asthmatic children
Source: Eur Respir J 2006; 28: Suppl. 50, 258s
Year: 2006
Volatile organic compounds (VOC) in exhaled breath of patients with COPD
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010
The application of mass spectrometry to the analysis and characterization of protein and peptide composition in exhaled breath condensate of pneumo-oncological diseased persons
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
Value of exhaled volatile organic compounds in monitoring airway disease
Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases
Year: 2013
Liquid chromatography-mass spectrometry (LC/MS) detects biomarker proteins in exhaled breath condensate (EBC) from endotracheally intubated patients collected at the exhaust port of a ventilator
Source: Eur Respir J 2006; 28: Suppl. 50, 549s
Year: 2006
Adaptation of differential ion mobility spectrometry (DMS) for discrimination of specific biomarkers in exhaled breath in patients with severe renal-pulmonary dysfunction
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
Liquid chromatography/mass spectrometry analysis of leukotriene B
4
in exhaled breath condensate in asthmatic children
Source: Eur Respir J 2005; 26: Suppl. 49, 41s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept